Peri-Implantitis: Diagnosis, Prevention, and Treatment

Peri-implantitis is a pathological inflammatory condition affecting the soft and hard tissues surrounding an osseointegrated dental implant, characterized by progressive loss of supporting bone. It represents one of the most clinically consequential complications in implant dentistry, with prevalence estimates ranging from 19% to 65% of implant patients depending on diagnostic threshold criteria used (Derks & Tomasi, Journal of Clinical Periodontology, 2015). This page covers the definition, underlying mechanics, risk drivers, classification frameworks, clinical debates, and documented treatment approaches associated with peri-implantitis.

Definition and Scope

Peri-implantitis is formally defined by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions as a plaque-associated pathological condition occurring in tissues around dental implants, characterized by inflammation in the peri-implant mucosa and subsequent progressive loss of supporting bone (2017 World Workshop Consensus Report, Journal of Clinical Periodontology, Supplement 20). This definition distinguishes peri-implantitis from peri-implant mucositis, which involves soft tissue inflammation without bone loss.

The scope of the problem is substantial at a population level. A systematic review published in Clinical Oral Implants Research (Salvi et al., 2017) placed weighted mean prevalence of peri-implantitis at approximately 22% of implant subjects across studies using radiographic bone loss thresholds of ≥2 mm combined with bleeding on probing. The condition can manifest as early as the first year post-placement but is more commonly diagnosed after 3 or more years of implant function.

Regulatory framing for dental implants in the United States falls under the U.S. Food and Drug Administration (FDA), which classifies endosseous dental implants as Class II or Class III medical devices under 21 CFR Part 872. The FDA's Center for Devices and Radiological Health (CDRH) requires cleared or approved devices to meet biocompatibility and mechanical performance standards, but post-market surveillance of biological complications like peri-implantitis is largely managed through the MedWatch voluntary reporting program and mandatory Medical Device Reporting (MDR) regulations under 21 CFR Part 803.

Understanding peri-implantitis is integral to navigating the broader landscape of dental implant complications and applies to all implant system types.

Core Mechanics or Structure

The tissue architecture around a dental implant differs meaningfully from that surrounding a natural tooth. Natural teeth are surrounded by a periodontal ligament (PDL) containing Sharpey's fibers that insert perpendicularly into cementum and alveolar bone, creating a vascularized, cellular cushion. Implants lack this ligament entirely; soft tissue attaches to the titanium or zirconia surface through hemidesmosomes and a long junctional epithelium, with collagen fibers running predominantly parallel or oblique to the implant surface rather than inserting into it.

This structural difference has two critical consequences. First, the biological seal around an implant is mechanically weaker and less able to resist apical migration of the junctional epithelium. Second, the absence of a PDL means there is no periodontal ligament vascularity to mount an early immune response; the peri-implant mucosa is relatively hypovascular compared to gingival tissue.

When bacterial biofilm accumulates at or below the mucosal margin, the resulting inflammatory infiltrate extends rapidly into the connective tissue and toward the crestal bone. The host immune response — involving interleukin-1β, interleukin-6, tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMPs) — drives osteoclast activation and irreversible bone resorption. Unlike natural tooth periodontitis, where bone loss can stabilize, peri-implantitis bone loss tends to follow a non-linear, accelerating pattern documented in longitudinal studies (Fransson et al., Journal of Clinical Periodontology, 2009).

The implant surface texture also plays a mechanistic role. Roughened surfaces that improve osseointegration — sandblasted and acid-etched (SLA) surfaces, for example — also retain biofilm more tenaciously once contaminated, making decontamination during treatment more difficult.

Causal Relationships or Drivers

The primary etiological driver is microbial biofilm — specifically, a shift from a commensal gram-positive aerobic flora to a pathogenic gram-negative anaerobic community colonizing the peri-implant sulcus. Pathogens documented in peri-implantitis lesions include Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, and Prevotella intermedia (Mombelli & Décaillet, Journal of Clinical Periodontology, 2011).

Established risk drivers beyond microbial load include:

Classification Boundaries

The 2017 World Workshop established a staging framework for peri-implantitis that parallels the periodontal staging system. Peri-implantitis is classified based on:

  1. Probing depth at the affected site relative to post-restoration baseline
  2. Radiographic bone loss expressed as a percentage of implant length or absolute millimeter measurement
  3. Bleeding on probing (BOP) and/or suppuration as indicators of active inflammation
  4. Complexity factors including furcation involvement equivalent (implant body exposure), vertical defect morphology, and implant mobility

Critically, the 2017 consensus distinguishes peri-implantitis from peri-implant mucositis — a reversible precursor condition involving BOP without bone loss, analogous to gingivitis — and from failed osseointegration at implant placement, which is a distinct entity.

The European Federation of Periodontology (EFP) S3-level clinical practice guideline on peri-implantitis (Herrera et al., 2023, Journal of Clinical Periodontology) further differentiates defect morphology as an important variable affecting treatment selection: circumferential intrabony defects generally show better outcomes with regenerative approaches than supra-crestal horizontal bone loss patterns.

Tradeoffs and Tensions

Peri-implantitis treatment presents documented clinical tensions that have not been resolved by consensus.

Non-surgical vs. surgical decontamination: Non-surgical mechanical debridement alone has a limited ability to achieve sufficient decontamination of rough implant surfaces, especially at probing depths ≥6 mm. A randomized controlled trial by Renvert et al. (Journal of Clinical Periodontology, 2009) demonstrated that non-surgical therapy reduced inflammation but rarely arrested bone loss in sites with initial bone loss >3 mm. Surgery provides access but introduces morbidity and does not guarantee disease resolution.

Implant surface decontamination methods: Multiple agents have been studied — citric acid, chlorhexidine, hydrogen peroxide, photodynamic therapy, and laser ablation — yet no single method has demonstrated consistently superior outcomes in systematic reviews. The American Academy of Periodontology (AAP) notes in its position paper that the evidence base for adjunctive decontamination protocols remains insufficient to recommend one over another (AAP Position Paper on Peri-Implant Mucositis and Peri-Implantitis, 2013).

Regenerative vs. resective surgery: Regenerative approaches using bone grafts and barrier membranes aim to recover lost bone volume, while resective surgery modifies site anatomy to reduce pocket depth. Regenerative outcomes are more variable and depend heavily on defect morphology. Neither approach reliably eliminates disease in all cases.

Implant removal thresholds: No universally accepted threshold for implant removal based on bone loss percentage exists. Clinical decisions weigh remaining bone support, patient systemic status, implant function, and restorability. This tension is explored further in the context of dental implant failure causes.

Common Misconceptions

Misconception: Implants cannot get infected the way natural teeth do.
Correction: While implants are not subject to caries, the peri-implant tissues are fully susceptible to bacterial-driven inflammatory destruction. The absence of a periodontal ligament means the progression, once established, may be faster and less reversible than periodontitis.

Misconception: Bone loss around an implant always signals implant failure requiring removal.
Correction: Early-to-moderate bone loss detected during maintenance can be managed with treatment, and many implants with documented peri-implantitis remain functional after intervention. The regulatory framework governing implant device performance — reviewed in the regulatory context for dental implants — addresses long-term functional expectations but does not define bone loss thresholds for removal.

Misconception: Peri-implantitis only affects poorly placed or low-quality implants.
Correction: The condition has been documented across all major implant systems, including those with FDA 510(k) clearance or PMA approval. Surface characteristics, maintenance quality, and patient-specific risk factors are more predictive than brand or system alone.

Misconception: Daily brushing alone is sufficient to prevent peri-implantitis.
Correction: Interproximal cleaning, professional maintenance intervals, and site-specific aids (such as interdental brushes sized to implant spacing) are components of prevention protocols identified in clinical guidelines. The long-term dental implant care framework addresses maintenance structure in detail.

Misconception: Antibiotics reliably treat peri-implantitis.
Correction: Systemic or local antibiotics are considered adjunctive, not primary, treatment. The EFP S3 guideline (Herrera et al., 2023) does not recommend antibiotics as a standalone therapy and notes concerns about antimicrobial resistance with repeated antibiotic use in this indication.

Checklist or Steps (Non-Advisory)

The following describes the documented diagnostic and treatment sequence used in clinical protocols for peri-implantitis, drawn from the EFP S3 clinical practice guideline (2023) and the AAP/EFP consensus classification (2017). This is a structural description of protocol steps, not a substitute for professional evaluation.

Diagnostic Assessment Phase
- [ ] Record full-mouth plaque score and bleeding on probing index at implant sites
- [ ] Measure probing depths at 4–6 points per implant using a calibrated periodontal probe with ≤0.25 N force
- [ ] Assess presence of suppuration at implant sites
- [ ] Obtain standardized periapical radiographs using a paralleling technique to evaluate crestal bone levels
- [ ] Compare current radiographs to post-loading baseline radiographs for bone loss quantification
- [ ] Document keratinized mucosa width at buccal aspect of each implant
- [ ] Review patient risk factors: periodontal history, smoking status, glycemic control, medication history

Risk Factor Modification Phase
- [ ] Implement or reinforce oral hygiene instruction specific to implant sites
- [ ] Address modifiable systemic risk factors (glycemic management, smoking cessation referral where applicable)
- [ ] Remove or evaluate existing prosthetic restorations for cement excess or occlusal discrepancies

Non-Surgical Treatment Phase
- [ ] Mechanical debridement of implant surface using carbon fiber curettes, titanium instruments, or ultrasonic devices with implant-compatible tips
- [ ] Apply adjunctive local or systemic antimicrobials per treating clinician's protocol if indicated
- [ ] Re-evaluate clinical parameters at 8–12 weeks post-treatment

Surgical Treatment Phase (if non-surgical insufficient)
- [ ] Select surgical approach based on defect morphology: resective (for horizontal/supracrestal loss), regenerative (for intrabony circumferential defects), or combined
- [ ] Perform implantoplasty of exposed implant surface threads if resective approach is used
- [ ] Place bone graft and/or barrier membrane if regenerative approach is selected
- [ ] Re-evaluate outcomes at 6 months post-surgery

Maintenance Phase
- [ ] Enroll patient in structured supportive peri-implant therapy at 3–6 month intervals
- [ ] Re-baseline radiographic records post-treatment
- [ ] Monitor for recurrence using probing depth, BOP, and radiographic comparisons at each maintenance visit

An overview of where peri-implantitis fits within the full spectrum of implant outcomes is available on the dental implants authority home page.

Reference Table or Matrix

Parameter Peri-Implant Mucositis Peri-Implantitis (Early) Peri-Implantitis (Moderate–Advanced)
Bone loss vs. baseline None ≥0.5 mm to <25% implant length ≥25% implant length or ≥3 mm absolute
Bleeding on probing Present Present Present, often with suppuration
Probing depth Variable; no increase from baseline ≥4 mm at affected site ≥6 mm typical; may reach implant apex
Reversibility Fully reversible with biofilm control Partially reversible with treatment Rarely fully reversible; management-dependent
Primary treatment Non-surgical debridement + oral hygiene Non-surgical + risk factor modification Surgical access ± regeneration or resection
Implant mobility Absent Absent Present only if total osseointegration loss
Radiographic features None Crestal resorption >1.5 mm Crater-like or angular bony defect
EFP S3 Guideline recommendation Conservative management Mechanical + adjunctive as needed Surgical; consider explantation if non-responding

Classification thresholds sourced from the 2017 World Workshop Consensus Report on the Classification of Periodontal and Peri-Implant Diseases (Berglundh et al., Journal of Periodontology Supplement, 2018).

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)